Health Step Finland Oy

Verified siteinfo

Finland Viestikatu 3, 70600 Kuopio, Finland

3 trials recruiting
Obesity · Type 2 diabetes mellitus · Arteriosclerosis
Adult patients

About Specializations

Health Step Finland Oy in Kuopio, Finland specialises in clinical trials of conditions such as Obesity, Type 2 diabetes mellitus, Arteriosclerosis, Overweight, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The study evaluates asundexian against apixaban to reduce risk of stroke in patients with atrial fibrillation, aiming to improve prevention of stroke or systemic embolism.

Comparison of novel anticoagulant with standard therapy
Assessment of major bleeding risk
Evaluation of overall benefit‑risk profile

Health Step Finland Oy conducts this cardiovascular research at its Kuopio facility, contributing to safer anticoagulation options.

Nutritional and Metabolic Diseases

The trial investigates whether survodutide added to a reduced‑calorie diet and increased physical activity can produce greater weight loss in adults with obesity, focusing on efficacy and safety.

Weight reduction efficacy
Safety and tolerability assessment
Impact on weight‑related complications

Conducted in Kuopio, Finland, this research by Health Step Finland Oy explores new therapeutic options for managing obesity without diabetes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Viestikatu 370600 KuopioFinland

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 10
Partner status: Verified site

More sites in Kuopio Finland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

10 clinical trials

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma AG

Contact Research Centre

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Obesity

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational

Finland

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites